Phase II Study Of The Impact Of AZD4017, A Selective 11bHSD1 Inhibitor, On Biochemical Markers Of Bone Turnover In Post-Menopausal Osteopaenia
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
Price : $35 *
At a glance
- Drugs AZD 4017 (Primary)
- Indications Metabolic bone diseases
- Focus Therapeutic Use
- 22 Oct 2015 Accrual to date is 8%, according to United Kingdom Clinical Research Network record.
- 28 May 2015 Status changed from not yet recruiting to recruiting as per United Kingdom Clinical Research Network.
- 16 May 2015 Status changed from suspended to recruiting, as reported by United Kingdom Clinical Research Network record.